Sir: Confusion has arisen in the literature concerning the association of serum antineuronal antibodies and paraneoplastic neurological disorders,' due partly to lack of standardisation of serological nomenclature and methodology, and partly to inadequate definition of antibody specificities. This is unfortunate, because clinical-serological correlations obtained in our recent screening for two distinct antibody specificities in a clinical laboratory indicate that simple indirect immunofluorescence testing2 is a valuable aid in establishing the paraneoplastic nature of certain neurological disorders. When positive, the procedure described below has the potential for enabling 1) inapparent cancer to be detected early enough to possibly effect a cure, and 2) antitumour treatment to be initiated before neurological impairment is severely disabling.
For clinical purposes, it is our practice to screen sera for anti-neuronal antibodies at 1:60 dilution, using unfixed frozen sections (6 p) of cerebellum (human, and mouse or guinea pig) and fluoresceinated polyvalent anti-human IgG2. Two 
